anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diuretics are medications that promote the excretion of water and electrolytes. They are primarily used in the management and treatment of states of inappropriate salt and water retention. Diuretics represent one of the most common classes of drugs administered to sick neonates, the more so in very low birth weight infants. Diuretic drugs, especially loop diuretics, are often administered in the neonatal intensive care unit as off-label medications. This is the case for a variety of clinical situations, in which an increase in sodium excretion is not the primary goal of treatment (transitory tachypnoea of the newborn at term, hyaline membrane disease, patent ductus arteriosus of preterm infants). Thiazides and furosemide are widely used to treat preterm infants with oxygen-dependent chronic lung disease, despite a lack of data on beneficial effect of long-term therapy on pulmonary function or clinical outcome. This article reviews the mechanism of action, indications, administration, posology, adverse effects and contraindications of diuretics in newborn infants. Based on the most recent information available in the literature, we will discuss data supporting (or questioning) the use of diuretic in specific neonatal diseases. Research priorities over this issue will be briefly presented.
The solid tumor treating medicine composition is one kind of slow releasing injection comprising slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material. The effective anticancer component is composition of chemotherapeutic synergist and topomase inhibitor and/or tetrazine medicine. The solvent is special solvent containing suspending agent. The slow releasing supplementary material is selected from lactic acid copolymer, polyethylene glycol/polylactic acid, glycolic acid copolymer, etc; the suspending agent has viscosity of 100cp-3000cp at 20-30 deg.c and is selected from carboxymethyl cellulose, etc. The solid tumor treating medicine composition may be also prepared into slow releasing implant. The slow releasing injection and the slow releasing implant may release medicine locally for 30-50 days.
This is a 2-part, Phase 2a, non-randomized, open-label multicenter, multinational study of intravenous ceftazidime-avibactam in hospitalized neonates and infants with suspected or confirmed bacterial infection. In Part A of the study, patients already receiving intravenous antibacterial therapy with another antibiotic will receive a single intravenous dose of ceftazidime-avibactam followed by observation for 48 hours and a Late Follow-Up assessment 4-5 weeks later. In Part B of the study, patients with suspected or confirmed Gram-negative bacterial infections requiring intravenous antibacterial therapy will receive multiple doses of intravenous ceftazidime-avibactam for up to 14 days. At the discretion of the investigator, patients may also receive other antibiotics if the infection is suspected to include Gram-positive bacteria, multi-drug resistant Gram-negative bacteria, or anaerobic bacteria. At the discretion of the investigator, patients may be switched to oral therapy or outpatient parenteral antimicrobial therapy with an alternative antibiotic after receiving intravenous ceftazidime-avibactam for at least 48 yhours. Clinical outcomes will be assessed at the End of Intravenous (EOIV) treatment with ceftazidime-avibactam, the End-of-Therapy (EOT), the Test-of-Cure (TOC) at 7-14 days after the last study therapy and at a Late Follow-Up (LFU) visit, 28-55 days after the last dose of ceftazidime-avibactam. Safety assessments will occur throughout the study. Ceftazidime-avibactam blood levels will be assessed during the first 12 hours after the single dose of ceftazidime-avibactam in Part A and during 12 hours after at least 3 consecutive doses of ceftazidime-avibactam in Part B.
The present invention describes the use of conjugated peptide sequences enclosed in liposome membranes. Conjugation can be with a folic acid or an antibody of the folic acid receptor, which is coupled to the N-terminal of the peptide. The presence of these conjugated peptides in liposome formulations allows therapeutic agents and/or imaging agents to be specifically targetted to and subsequently released in cells with expression of folic acid receptors. The thus developed method allies the capacity of liposomes to transport and release drugs with the specific expression of receptors at the surface of cell membranes, allowing transmembrane transport mediated by specific liposomes. It thus can transport both hydrophobic and hydrophilic therapeutic and/or imaging agents inside the liposome. The therapeutic agents can be pharmacological compounds - active principles - or small interfering RNAs (siRNAs) specific to defined target genes.
This study is double-blind, placebo-controlled, 1:1 randomized clinical therapeutic trial of acetazolamide for the treatment of ataxia in patients with PMM2-CDG. Clinical history and screening data will be reviewed to determine subject eligibility. Potential subjects who have a molecularly and/or biochemical confirmed diagnosis of PMM2-CDG will be consented. Baseline data will be collected prior to randomization and at treatment initiation. Subjects who meet all inclusion criteria and none of the exclusion criteria will be enrolled into the study. Each subject who meets all the inclusion and none of the exclusion criteria will then be randomized to placebo or acetazolamide. They will be administered weight-dependent doses of acetazolamide or an equivalent volume of placebo twice daily by mouth. Initial dose of acetazolamide is 8 mg/kg/day if subjects are taking the liquid formulation, or as per Table 1b if they are taking the capsule formulation. If taking the liquid formulation, the dose of study drug will be increased by 7 mg/kg/day to a maximum of 22 mg/kg/day (not to exceed 1000 mg/day) if well tolerated with no treatment related SAEs or abnormal pH. If the pH is \<7.32, the dose will be reduced by 7 mg/kg/day. The dose will be adjusted similarly according to Table 1b if taking the capsule formulation. Subjects will be randomized after Visit 1, will initiate blinded therapy within the first week, and will continue on prescribed/adjusted blinded treatment until Visit 4. Of note, the concentration of the liquid formulation and the amount of milligrams of acetazolamide per capsule will stay constant, and the volume or number of capsules will be adjusted based on tolerance as assessed by symptoms and laboratories. If an individual is randomized to the placebo arm, the initial volume will be equivalent to 7 mg/kg/day or the initial number of capsules as per Table 1, and volume or number of capsules will also be adjusted based on symptoms and laboratory values each time dose adjustment is planned. Open label period will then begin after Visit 4 up to Visit 9 (see Figure 1 and Table 3). As both the subject and investigator do not know if the subject received placebo or acetazolamide, the dose of acetazolamide will be started at Visit 4 at 8 mg/kg/day and titrated upwards in the same manner in Visits 5 and 6 (remote) as in Visits 2 and 3 (remote). Subjects will have the option to withdraw from the study any time after Visit 4 if they do not wish to proceed onto or continue with the open label phase.
The present invention relates to a composition and a preparing method thereof, which comprises locust fruit, grape pips and bark extract. The existing soybean isoflavone mainly comprises various flavonoid compound mixtures of genistin, soy bean glycoside, etc., and exists in a glycoside state. However, the soybean isoflavone can be absorbed and utilized by a human body through the decomposition of an intestinal canal of the human body, and the activity of the soy bean glycoside is much lower than that of the genistein. Moreover, osteoporosis therapeutic medicine comprises estrogen, but cancers caused by taking the estrogen in a long term are reported. The present invention relates to the composition of the extract of the locust fruit which comprises genistein and the extract of the grape pips and bark which comprise procyanidin. The present invention adopts a biochemical method that the locust fruit, the grape pips and the bark are used as raw materials for preparing medicine which has the healthcare effects of bone density increase, oxidation resistance, climacteric symptom relief, cardiovascular disease control, etc. The medicine is tested on 200 people, and clinical observation proves that overall therapeutic efficacy is good, and an effective rate reaches more than 95 percent. In addition, the present invention has the advantages of safety, high efficiency and no adverse reaction and side effects.
The invention particularly discloses a kind of Chinese medicine compositions and its preparation method and application for treating psoriasis；The Chinese medicine composition that the present invention treats psoriasis includes following raw material: Chinese medical extract, moisturizer, cutaneous permeable agent, surfactant, emulsifier and matrix.The Chinese medicine composition preparation method comprises the steps of: that S1. takes various Chinese medicine material warm water to impregnate 30~45min；S2. 1~1.5h of refluxing extraction will be carried out by medicinal water among the above, and 65~80 DEG C of temperature, will take filtrate；S3. above-mentioned filter residue is subjected to 1.5~2h of refluxing extraction with water again, takes filtrate, abandon filter residue；S4. summarize filtrate, and be concentrated under reduced pressure to give Chinese medical extract；S5. then, dissolution is mixed to get matrix solution in various other components；S6. Chinese medical extract is added in matrix solution again, is uniformly mixed；S7. carried out homogeneous again, at room temperature place 2~3h to get.
This is an animal model study to investigate changes in hemostasis during endotoxemic shock and to determine whether the combination of inhaled nitric oxide (iNO) + intravenous hydrocortisone had an effect on clot formation and fibrinolysis. iNO selectively decreases pulmonary artery pressure, without affecting cardiac index or systemic vascular resistance; however, the results of studies on the possible consequences of iNO administration on coagulation are inconsistent and require further research. Thirty-four piglets were included. Administering endotoxin caused severe hypodynamic shock. Half of the animals received iNO (30 ppm) + hydrocortisone, starting 3 h after endotoxin infusion and continuing to the end of the study. All animals developed coagulation disorders, manifested by a tendency to hypocoagulation; at the same time, fibrinolysis was impaired. Coagulation and fibrinolysis disorders persisted after endotoxin infusion was discontinued, with worse severity in the animals that died before the study was terminated. Administering iNO + hydrocortisone did not cause further changes in coagulation and fibrinolysis parameters, either during or after the endotoxin challenge, suggesting that potential therapeutic interventions with iNO to lower pulmonary arterial pressure will not affect hemostasis.
A light curable synthetic resin material including a mixture of a light curable synthetic resin and a dye, the absorption and fluorescence of which depend on the degree of curing of the resin. <??>A light curable synthetic resin material including a mixture of a light curable synthetic resin and a dye, the absorption and fluorescence of which depend on the degree of curing of the resin. <??>Certain dyes which show absorption or fluorescence on radiation with light of wavelength producing curing of light curable synthetic resins and are suitable for indicating the degree of light curing of these when embedded in the resin, and require only a very small amount of this dye sufficient to convert the resin to a material of optical properties e.g. fluorescence and absorption, clearly dependent on the degree of resin curing. <??>Independent claims are included for: <??>(1) a light cured liner for cladding of pipes, including a carrier material, a light curable synthetic resin, and a dye as above; <??>(2) a system for pipe cladding including a light curable synthetic resin impregnated liner, one or more illumination units (sic) for (a) radiation in a first wavelength region for curing of the liner and (b) radiation in a second wavelength region for absorption via the dye of the light curable synthetic resin material and/or its fluorescence excitation, a receiver for receiving information on the absorption or fluorescence behavior of the light curbable resin on radiation with light of the second wavelength; <??>(3) a process for determination of the degree of curing of the light curable resin, where the resin is mixed in the uncured state with the dye, the absorption and/or fluorescence of which depends on the degree of curing of the resin, and determination of the absorption and/or fluorescence behavior of the dye; and <??>(4) a process for curing a light curable synthetic resin involving the steps of: radiation of a liner or light curable synthetic resin with light of the first wavelength so that curing of the light curable resin takes place, radiation of the liner or light curable resin with light of a second wavelength to detect absorption and/or fluorescence of the light curable, dye containing synthetic resin material, where the two wavelength regions are different and the radiation of the liner or light curable resin with light of the first wavelength region, as a function of the absorption and/or fluorescence from radiation with light of the second wavelength is controlled by the dye in the light curable resin material.
Inflammatory Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis) and scleroderma participants in this group will attend an 8 week MBSR course. The MBSR course meets once per week for 2.5 hours with a 4-hour retreat on week 8.
OBJECTIVES: I. Determine the maximum tolerated dose of decitabine in patients with relapse post allogenic bone marrow transplant. II. Determine the toxicity of decitabine combined with filgrastim (G-CSF) primed allogeneic peripheral blood stem cells in patients who relapsed within 1 year after allogeneic bone marrow transplantation. III. Determine the effectiveness in reinducing remission in these patients.

OUTLINE: Patients receive decitabine IV for 6 hours every 12 hr for 5 days. Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine. Donors receive filgrastim subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection. If insufficient number of cells are collected, bone marrow can be harvested for supplementation. Donor cells should be collected prior to decitabine infusion. Patients receive filgrastim SQ administered daily starting 1 day after PBSC infusion until blood counts recover. For GVHD prophylaxis, patients receive cyclosporine IV daily on day -2, then orally once dose is tolerable. Dose of decitabine is escalated in cohorts of 3-6 patients. If dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then that dose is declared the maximum tolerated dose. Patients are followed weekly. If none of the first 5 patients survive in remission for more than 100 days, the study will be terminated.

PROJECTED ACCRUAL: At least 15 patients will be accrued for this study over 2 years.
Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring \& Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring \& Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
There is limited premarketing clinical experience with the effects of an overdosage of HETLIOZ.

As with the management of any overdose, general symptomatic and supportive measures should be used, along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Respiration, pulse, blood pressure, and other appropriate vital signs should be monitored, and general supportive measures employed.

While hemodialysis was effective at clearing HETLIOZ and the majority of its major metabolites in patients with renal impairment, it is not known if hemodialysis will effectively reduce exposure in the case of overdose.

As with the management of any overdose, the possibility of multiple drug ingestion should be considered. Contact a poison control center for current information on the management of overdose.
A Chinese treatment protocol would be developed based on the UP-A. The adolescent program consists of 8 modules, and the parent program consists of 3 modules. Similar to the work by Ehrenreich and Barlow, a flexible modular approach would be adopted, when extra sessions would be arranged to cater for individual treatment needs and heterogeneity of symptom severity. The whole treatment comprised of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardian. The total duration would be around 3 months. Each treatment sessions would be around 1 hour.
The peritoneal cavity of subjects will be washed with 2 liters or less of warmed normal saline. The abdomen will be closed as per standard.
For the rehabilitation of the paretic upper extremity, the use of constraint induced movement therapy and the use of modified constraint induced movement therapy are the most effective treatment strategies. The investigators aimed To analyze effect of modified constraint induced movement therapy on upper extremity functions and quality of life of subacute and chronic phase stroke patients with right/left hemisphere damage.

A total of 40 patients (20 patients with right hemiplegia and 20 patients with left hemiplegia) were enrolled in our prospective, randomized and controlled trial. Patients were randomized in to three groups. The first group consists of 10 right hemiplegia patients and the second group consists of 10 left hemiplegia patients. First and second group of patients had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake. 10 patients with right hemiplegia and 10 patients with left hemiplegia formed the control group and these patients were in line for inpatient rehabilitation programme. Patients were examined before treatment, just after treatment and 3 months after treatment using Box-Block Test, cubes lined, card turned and object gripped in 30 seconds, time it takes to grip and carry a water filled glass to their mouth and putting it back, Motor Activity Log (MAL), Stroke Impact Scale, Fugl-Meyer Motor Assessment Scale. Wilcoxon Signed Ranks test and Friedman test were used for intragroup comparison of data and Kruskal-Wallis test was used to compare data between groups.
Participants received 20 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 4 weeks, and each training session lasted 1 hour .Patients allocated to the Control Group performed a general exercise program and a conventional gait training with a 5-minute rest between them. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long.
INTRODUCTION: The relationship between social determinants of health (SDOH) and health-related social needs (HRSN) and some chronic diseases at the population level is not well known. We sought to determine relationships between SDOH/HRSN and major chronic diseases among US adults by using data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS).
METHODS: We used data from the new Social Determinants and Health Equity (SD/HE) module, conducted in 39 states, the District of Columbia, and 2 territories as part of the 2022 BRFSS. These data yielded a sample of 324,631 adult participants (aged ≥18 y). We examined 12 indicators of SDOH/HRSN and 9 chronic diseases. We calculated weighted prevalence estimates for each SDOH/HRSN measure for each chronic disease and associations between each SDOH/HRSN and each chronic disease.
RESULTS: Two-thirds of participants (66.3%) had 1 or more chronic diseases, and 59.4% reported 1 or more adverse SDOH/HRSN. Prevalence estimates for individual SDOH/HRSN measures were generally higher among participants with chronic diseases (except cancer). The more chronic diseases reported, the more likely participants were to have SDOH/HRSN (P < .05 for linear trend). The leading SDOH/HRSN measures associated with each chronic disease varied; however, the most common were mental stress, receiving food stamps or participating in the Supplemental Nutrition Assistance Program, cost as a barrier for needed medical care, and life dissatisfaction.
CONCLUSION: From a treatment and prevention perspective, health care providers should consider the influence of SDOH/HRSN on people with or at risk for chronic diseases. Additionally, human service and public health systems in communities with high rates of chronic disease should consider these findings as they plan to mitigate adverse SDOH.
Arm II: Docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days.
PURPOSE:To obtain a paint for hemorrhoids effective for blind piles, bleeding piles, etc. by synergistic effect of extracted components and salt, obtained by dococting leaves of Houttuynia cordata Thunb and Ficus carica with a salt solution in a specific ratio, being used in a solution of salt. CONSTITUTION:1-5pts.wt. Houttuynia cordata Thunb and 1-5pts.wt. Ficus carica together with 2-10pts.wt. salt are put in a container, heated with preferably 150-200 times as much water as dried materials, decocted until the solution is concentrated to about 1/2 amount of the solution, to give a paint for hemorrhoids. When it is used, the paint is used in a solution at 40-60 deg.C. The paint sterilizes and disinfects the affected part by mild effect on hemorrhoids, especially blind piles, bleeding piles, archoptosis, etc., stops bleeding by anti-inflammatory and analgesic action, regenerate the cell of the affected part well, remedies it. The paint promotes circulation of blood and increases remedying effect.